Over the past four years, one question has repeatedly surfaced within the UK hemp and CBD industry: how did certain CBD products, including those linked to Pureis, come to be included on the Food Standards Agency CBD Public List despite clear requirements that products had to be on the market before 13 February 2020? This article examines the evidence, correspondence, FOI disclosures, and complaint files surrounding that question.

When a fixed regulatory deadline meets withheld evidence and shifting interpretations, questions follow. This open letter examines how the UK Food Standards Agency has applied its CBD novel foods rules—and whether those decisions can be properly scrutinised.

To me, both May’s and Atkins’ paths highlighted what I think is the biggest conflict... the dinner conversation.

Despite the FSA’s assurance that assessments will continue, it is difficult to see how any applications could progress much further. Furthermore, authorisations ultimately require ministerial approval, and it is those same ministers who are currently negotiating the SPS agreement rather than the FSA.

The original use of “Business As Usual” was during wartime, a deliberate attempt to maintain public calm while the world collapsed around them. So the question is this: What war, exactly, is the FSA trying to normalise? Against transparency, perhaps? If that is the case, it's interesting that it started at a time that is significant for CBD Novel Foods. That is provable through the 2021 FSA FOI report, which, other than a modified response on 17/06/21, shows an abrupt stop

This is bigger than novel foods. This is about regulatory manipulation and undeclared conflicts of a senior Civil Servant when investigating a complaint that was made in the public interest.

How did 'Skunk' end up on an MHRA Yellow Card list meant for medicines and vaccines? And why does the timeline perfectly align with GW Pharm